Outer Biosciences operates the Yuna platform, which the company says sustains full-thickness human skin (epidermis, dermis and resident immune cells) ex vivo for up to four weeks—significantly longer than the typical three to seven days. The platform is fed by a biobank of tissue from over 300 donors across phototypes I–VI and produces biological readouts used to train an AI that proposes molecules to test. Outer reports six active compounds in development and estimates four may reach market, though it currently has no products on shelves. The company publishes its platform data as a preprint on bioRxiv and notes limitations of the current system, including lack of recruitment of circulating immune cells and absence of vascular perfusion. Outer was founded in 2022 and derives revenue from research partnerships, including collaborations with a pharmaceutical company.

Total raised

$23M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2026